# Pharmaceuticals Financial Models

Canonical: https://finamodel.com/sectors/pharmaceuticals

A medicine can fund years of research before losing sales rapidly when exclusivity ends. New launches must replace that income, but development spending does not guarantee an approved product. A pharmaceutical forecast needs to reflect the age of the portfolio as well as its current growth.

Page 1 of 1

- [Johnson & Johnson](https://finamodel.com/companies/johnson-johnson)
- [Merck & Co.](https://finamodel.com/companies/merck)
- [Pfizer](https://finamodel.com/companies/pfizer)
- [AbbVie](https://finamodel.com/companies/abbvie)
- [Bristol Myers Squibb](https://finamodel.com/companies/bristol-myers-squibb)
- [Lilly (Eli)](https://finamodel.com/companies/lilly-eli)
- [Amgen](https://finamodel.com/companies/amgen)
- [Gilead Sciences](https://finamodel.com/companies/gilead-sciences)
- [Viatris](https://finamodel.com/companies/viatris)
- [Regeneron Pharmaceuticals](https://finamodel.com/companies/regeneron-pharmaceuticals)
- [Vertex Pharmaceuticals](https://finamodel.com/companies/vertex-pharmaceuticals)
- [Biogen](https://finamodel.com/companies/biogen)
- [Zoetis](https://finamodel.com/companies/zoetis)
- [Moderna](https://finamodel.com/companies/moderna)
- [Incyte](https://finamodel.com/companies/incyte)